Pure Active Niacinamide 5%

• -13%*** in spot intensity and +46%*** in sallow complexion prevention ⁽¹⁾
• 5% is the right dose according to 3 independent clinical studies published in scientific literature ^(2)(3)(4) which showed a significant reduction in hyperpigmentation, decrease in red blotchiness and decrease skin yellowing (sallowness)
• IN-SKIN patented technology: diffusion booster to deliver the active ingredient exactly where it needs to go, with a X3 improvement of Pure Active diffusion into the skin ^(5).
• Suitable for sensitive skin ⁽¹⁾ Well tolerated ^(6).
• Quick penetration and non-oily⁽⁷⁾

 ***p<0.001, t-test

1. Clinical test under dermatological control, 33 volunteers aged from 31 to 64 years old, 100% sensitive skin, with pigmentary spots and uneven complexion. Twice-daily application on the face and neck, 56 days. Clinical scoring. 
2. Hakozaki, T et al. “The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer.” The British journal of dermatology vol.147,1 (2002): 20 31. doi:10.1046/j.1365 2133.2002.04834.x
3. Greatens, Amanda et al. “Effective inhibition of melanosome transfer to keratinocytes by lectins and niacinamide is reversible .” Experimental dermatology vol. 14,7 (2005): 498 508. doi:10.1111/j.0906 6705.2005.00309.x
4. Bissett, D L et al. “Topical niacinamide reduces yellowing , wrinkling , red blotchiness , and hyperpigmented spots in aging facial skin.” International journal of cosmetic science vol. 26,5 (2004): 231 8. doi:10.1111/j.1467 2494.2004.00228.x
5. Ex-vivo tests on Franz cells: comparison between the diffusion of a standard formula, containing IN-SKIN™ plus 2% caffeine (ingredient selected as example), and the diffusion of a standard formula containing only 2% caffeine (without IN-SKIN™)
6. Clinical test under dermatological control, 33 volunteers aged from 31 to 64 years old, 100% sensitive skin, with pigmentary spots and uneven complexion. Twice-daily application on the face and neck, 56 days. Evaluation of tolerance by dermatologist.  
7. Clinical test under dermatological control, 33 volunteers aged from 31 to 64 years old, 100% sensitive skin, with pigmentary spots and uneven complexion. Twice-daily application on the face and neck, 56 days. Self-assessment. 

> CLINICAL RESULTS

After 56 days of twice-daily application:

• Skin is lighter : +23%* in ITA° (individual typological angle)⁽¹⁾.
• - 13%*** ⁽⁹⁾ in spot intensity, -5%* in spot size⁽²⁾, +46%*** in sallow complexion prevention⁽²⁾, +9%** in skin uniformity ⁽²⁾ and +32%*** in skin radiance⁽²⁾.

> PATIENTS FEEDBACKS

After 56 days of twice daily application: 

• skin is more radiant and luminous (for 100% of subjects) ⁽³⁾
• skin is brighter (for 94% of them) ⁽³⁾
• skin is less yellowish (for 91% of them) ⁽³⁾
• pigment spots are reduced (for 85% of them) ⁽³⁾

1. Clinical test under dermatological control, 33 volunteers aged from 31 to 64 years old, 100% sensitive skin, with pigmentary spots and uneven complexion. Twice-daily application on the face and neck, 56 days. Spectrophotometry.  
2. Clinical test under dermatological control, 33 volunteers aged from 31 to 64 years old, 100% sensitive skin, with pigmentary spots and uneven complexion. Twice-daily application on the face and neck, 56 days. Clinical scoring. 
3. Clinical test under dermatological control, 33 volunteers aged from 31 to 64 years old, 100% sensitive skin, with pigmentary spots and uneven complexion. Twice-daily application on the face and neck, 56 days. Self-assessment